Effectiveness of fibrosis-4 versus aspartate aminotransferase-to-platelet ratio index in evaluating liver fibrosis degree in patients with chronic HBV infection
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 12
Abstract
[Objective] To investigate the performance of fibrosis-4 （FIB-4） versus aspartate aminotransferase-to-platelet ratio index （APRI） in predicting advanced liver fibrosis and disease progression in patients with chronic HBV infection. [Methods] A total of 497 patients with chronic HBV infection who underwent liver biopsy in The First Affiliated Hospital of Guangxi Medical University from February 2013 to December 2022 were enrolled， among whom 404 were enrolled in a retrospective study and 75 were enrolled in a prospective study. Related indicators were collected， including demographic features （sex and age）， biochemical indices （alanine aminotransferase ［ALT］ and aspartate aminotransferase ［AST］）， and platelet count， and FIB-4 and APRI were calculated. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups， and the Kruskal-Wallis H test was used for comparison between multiple groups； the chi-square test was used for comparison of categorical data between groups. The area under the ROC curve （AUC） was used to assess the ability of APRI and FIB-4 in evaluating liver fibrosis degree and disease progression in patients with chronic HBV infection. [Results] In the retrospective analysis， compared with the FIB-4<2.67 group， the FIB-4≥2.67 group had a significantly higher proportion of the patients who were diagnosed with liver cirrhosis or hepatocellular carcinoma （66.19% vs 47.54%， χ²=12.75， P<0.001）. The medians of FIB-4 and APRI increased significantly with liver fibrosis degree from F0 to F4 （H=42.5 and 35.9， both P<0.001）. As for the fibrosis stage of F0-F4， the median of FIB-4 was significantly higher than that of APRI in the patients with the same fibrosis stage （H=59.71， P<0.001）. FIB-4 and APRI had a similar AUC for predicting stage F3 fibrosis （0.67 vs 0.65， Z=0.71， P=0.480）， while FIB-4 had a higher AUC for predicting stage F4 fibrosis than APRI （0.72 vs 0.64， Z=10.50， P<0.001）. In the prospective study cohort， FIB-4 and APRI showed an increasing trend over time in predicting disease progression （chronic hepatitis B to liver cirrhosis）， with an AUC of 0.718 （95% confidence interval ［CI］： 0.476 — 0.760） and 0.555 （95%CI： 0.408 — 0.703）， respectively， and FIB-4 had a significantly higher accuracy than APRI in predicting disease progression （χ2=12.44， P<0.001）. [Conclusion] FIB-4 and APRI can be used to evaluate advanced liver fibrosis （F3 and F4） and predict disease progression， and FIB-4 is superior to APRI in certain aspects.
Authors and Affiliations
Xiaoting LI, Bobin HU, Hongyu LIU, Chao JIN, Cailian CAI, Keshan WANG, Yanchun WEI, Jianning JIANG, Minghua SU
Keywords
Related Articles
- EP ID EP753934
- DOI 10.12449/JCH241212
- Views 10
- Downloads 0
Effect of Xiayuxue Decoction against renal injury in mice with non-alcoholic fatty liver disease and its mechanism
[Objective] To investigate the effect of non-alcoholic fatty liver disease （NAFLD） induced by high-fat diet （HFD） on the kidneys of mice and the protective effect and mechanism of Xiayuxue Decoction. [Methods] A tota...
Research advances of noninvasive diagnosis of fibrotic non-alcoholic steatohepatitis
A subset of patients with non-alcoholic fatty liver disease （NAFLD） can progress to nonalcoholic steatohepatitis （NASH）. When NASH reaches a fibrosis degree of F≥2 and a NAS score of≥4， this stage of NASH is referre...
Effect of Qizhu prescription on a mouse model of non-alcoholic fatty liver disease incluced by high-fat， high-fructose， and high-cholesterol diet and its mechanism
[Objective] To investigate the therapeutic effect and mechanism of action of Qizhu prescription in mice with non-alcoholic fatty liver disease （NAFLD）. [Methods] A total of 60 male C57BL/6J mice were randomly divided i...
Interpretation of guideline for diagnosis and treatment of liver failure （2024 version）
In 2024， Liver Failure and Artificial Liver Group， Chinese Society of Infectious Diseases， Chinese Medical Association and Chinese Society of Hepatology， Chinese Medical Association updated Guideline for diagnosis an...
Effect of amino acid metabolic reprogramming on immune microenvironment of hepatocellular carcinoma
Tumor immune microenvironment is a local external tumor environment composed of tumor immune cells and the cytokines secreted by these cells， and it plays a regulatory role in the development and progression of tumors....